359 related articles for article (PubMed ID: 21554923)
1. Biomarkers in frontotemporal lobar degenerations--progress and challenges.
Hu WT; Trojanowski JQ; Shaw LM
Prog Neurobiol; 2011 Dec; 95(4):636-48. PubMed ID: 21554923
[TBL] [Abstract][Full Text] [Related]
2. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
[TBL] [Abstract][Full Text] [Related]
3. RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
Hofmann JW; Seeley WW; Huang EJ
Annu Rev Pathol; 2019 Jan; 14():469-495. PubMed ID: 30355151
[TBL] [Abstract][Full Text] [Related]
4. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
5. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
6. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.
Irwin DJ; Cairns NJ; Grossman M; McMillan CT; Lee EB; Van Deerlin VM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Apr; 129(4):469-91. PubMed ID: 25549971
[TBL] [Abstract][Full Text] [Related]
7. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
8. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
Neumann M
Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
[TBL] [Abstract][Full Text] [Related]
9. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
Mann DMA; Snowden JS
Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
[TBL] [Abstract][Full Text] [Related]
10. Frontotemporal lobar degeneration: diversity of FTLD lesions.
Seilhean D; Bielle F; Plu I; Duyckaerts C
Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
[TBL] [Abstract][Full Text] [Related]
11. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.
Rabinovici GD; Miller BL
CNS Drugs; 2010 May; 24(5):375-98. PubMed ID: 20369906
[TBL] [Abstract][Full Text] [Related]
12. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
13. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
[TBL] [Abstract][Full Text] [Related]
14. Genetic contribution of FUS to frontotemporal lobar degeneration.
Van Langenhove T; van der Zee J; Sleegers K; Engelborghs S; Vandenberghe R; Gijselinck I; Van den Broeck M; Mattheijssens M; Peeters K; De Deyn PP; Cruts M; Van Broeckhoven C
Neurology; 2010 Feb; 74(5):366-71. PubMed ID: 20124201
[TBL] [Abstract][Full Text] [Related]
15. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis.
Broustal O; Camuzat A; Guillot-Noël L; Guy N; Millecamps S; Deffond D; Lacomblez L; Golfier V; Hannequin D; Salachas F; Camu W; Didic M; Dubois B; Meininger V; Le Ber I; Brice A;
J Alzheimers Dis; 2010; 22(3):765-9. PubMed ID: 21158017
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum.
Van Langenhove T; van der Zee J; Van Broeckhoven C
Ann Med; 2012 Dec; 44(8):817-28. PubMed ID: 22420316
[TBL] [Abstract][Full Text] [Related]
17. A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.
Nakamura M; Bieniek KF; Lin WL; Graff-Radford NR; Murray ME; Castanedes-Casey M; Desaro P; Baker MC; Rutherford NJ; Robertson J; Rademakers R; Dickson DW; Boylan KB
Acta Neuropathol; 2015 Jul; 130(1):145-57. PubMed ID: 25917047
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
[TBL] [Abstract][Full Text] [Related]
19. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.
Seltman RE; Matthews BR
CNS Drugs; 2012 Oct; 26(10):841-70. PubMed ID: 22950490
[TBL] [Abstract][Full Text] [Related]
20. [Pathomechanisms and clinical aspects of frontotemporal lobar degeneration].
Bürger K; Arzberger T; Stephan J; Levin J; Edbauer D
Nervenarzt; 2017 Feb; 88(2):163-172. PubMed ID: 27999880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
